Tyrosine kinase inhibitors and modifications of thyroid function tests: A review

European Journal of Endocrinology

Volumn 160, Issue 3, 2009, Pages 331-336

  Illouz, Frédéric ^a   Laboureau Soares, Sandrine ^a   Dubois, Séverine ^a   Rohmer, Vincent ^a,b,c   Rodien, Patrice ^a,b,c  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

^c UNIVERSITÉ D'ANGERS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; LEVOTHYROXINE; MOTESANIB; SORAFENIB; SUNITINIB; THYROTROPIN; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ANTINEOPLASTIC ACTIVITY; ASPIRATION BIOPSY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL STROMAL TUMOR; HORMONAL THERAPY; HUMAN; HYPOTHYROIDISM; KIDNEY CARCINOMA; MULTIPLE CYCLE TREATMENT; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; THYROID CARCINOMA; THYROID FUNCTION TEST; THYROID HORMONE RELEASE; THYROID MEDULLARY CARCINOMA; THYROID SURGERY; THYROIDITIS; THYROTOXICOSIS; THYROTROPIN BLOOD LEVEL; THYROXINE METABOLISM; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; NEOPLASM;

HUMANS; HYPOTHYROIDISM; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; THYROID FUNCTION TESTS;

EID: 62649174250     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-08-0648     Document Type: Review

References (42)

1. Krause DS & Van Etten RA. Tyrosine kinases as targets for cancer therapy. New England Journal of Medicine 2005 353 172-187.
2. Le Tourneau C, Faivre S & Raymond E. New developments in multitargeted therapy for patients with solid tumours. Cancer Treatment Reviews 2008 34 37-48.
3. Rock EP, Goodman V, Jiang JX, Mahjoob K, Verbois SL, Morse D, Dagher R, Justice R & Pazdur R. Food and drug administration drug approval summary: sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist 2007 12 107-113.
4. http://www.fda.gov/cder/foi/label/2007/021968s005lbl.pdf.
5. Desai J, Yassa L, Marqusee E, George S, Frates MC, Chen MH, Morgan JA, Dychter SS, Larsen PR, Demetri GD & Alexander EK. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Annals of Internal Medicine 2006 145 660-664.
6. Mannavola D, Coco P, Vannucchi G, Bertuelli R, Carletto M, Casari P, Beck-Peccoz P & Fugazzola L. A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. Journal of Clinical Endocrinology and Metabolism 2007 92 3531-3534.
7. Rini BI, Tamaskar I, Shaheen P, Salas R, Garcia J,Wood L, Reddy S, Dreicer R & Bukowski RM. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. Journal of the National Cancer Institute 2007 99 81-83.
8. Wong E, Rosen LS, Mulay M, Vanvugt A, Dinolfo M, Tomoda C, Sugawara M & Hershman JM. Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid 2007 17 351-355.
9. Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, Woulfe K, Pravda E, Cassiola F, Desai J, George S, Morgan JA, Harris DM, Ismail NS, Chen JH, Schoen FJ, Van den Abbeele AD, Demetri GD, Force T & Chen MH. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007 370 2011-2019.
10. Wolter P, Stefan C, Decallonne B, Dumez H, Bex M, Carmeliet P & Schöffski P. The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. British Journal of Cancer 2008 99 448-454.
11. Faris JE, Moore AF & Daniels GH. Sunitinib (sutent)-induced thyrotoxicosis due to destructive thyroiditis: a case report. Thyroid 2007 17 1147-1149.
12. Grossmann M, Premaratne E, Desai J & Davis ID. Thyrotoxicosis during sunitinib treatment for renal cell carcinoma. Clinical Endocrinology 2008 69 669-672.
13. Kamba T, Tam BY, Hashizume H, Haskell A, Sennino B, Mancuso MR, Norberg SM, O'Brien SM, Davis RB, Gowen LC, Anderson KD, Thurston G, Joho S, Springer ML, Kuo CJ & McDonald DM. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. American Journal of Physiology. Heart and Circulatory Physiology 2006 290 H560-H576.
14. Baffert F, Le T, Sennino B, Thurston G, Kuo CJ, Hu-Lowe D & McDonald DM. Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. American Journal of Physiology. Heart and Circulatory Physiology 2006 290 H547-H559.
15. Viglietto G, Romano A, Manzo G, Chiappetta G, Paoletti I, Califano D, Galati MG, Mauriello V, Bruni P, Lago CT, Fusco A & Persico MG. Upregulation of the angiogenic factors PlGF, VEGF and their receptors (Flt-1, Flk-1/KDR) by TSH in cultured thyrocytes and in the thyroid gland of thiouracil-fed rats suggest a TSH-dependent paracrine mechanism for goiter hypervascularization. Oncogene 1997 15 2687-2698.
16. Yamada E, Yamazaki K, Takano K, Obara T & Sato K. Iodide inhibits vascular endothelial growth factor-A expression in cultured human thyroid follicles: a microarray search for effects of thyrotropin and iodide on angiogenesis factors. Thyroid 2006 16 545-554.
17. Jebreel A, England J, Bedford K, Murphy J, Karsai L & Atkin S. Vascular endothelial growth factor (VEGF), VEGF receptors expression and microvascular density in benign and malignant thyroid diseases. International Journal of Experimental Pathology 2007 88 271-277.
18. Hoffmann S, Hofbauer LC, Scharrenbach V, Wunderlich A, Hassan I, Lingelbach S & Zielke A. Thyrotropin (TSH)-induced production of vascular endothelial growth factor in thyroid cancer cells in vitro: evaluation of TSH signal transduction and of angiogenesis-stimulating growth factors. Journal of Clinical Endocrinology and Metabolism 2004 89 6139-6145.
19. Salem AK, Fenton MS, Marion KM & Hershman JM. Effect of sunitinib on growth and function of FRTL-5 thyroid cells. Thyroid 2008 18 631-635.
20. Carella C, Mazziotti G, Amato G, Braverman LE & Roti E. Clinical review 169: interferon-alpha-related thyroid disease: pathophysiological, epidemiological, and clinical aspects. Journal of Clinical Endocrinology and Metabolism 2004 89 3656-3661.
21. http://www.fda.gov/cder/drug/infopage/gleevec/default.htm.
22. de Groot JW, Zonnenberg BA, Plukker JT, van Der Graaf WT & Links TP. Imatinib induces hypothyroidism in patients receiving levothyroxine. Clinical Pharmacology and Therapeutics 2005 78 433-438.
23. de Groot JW, Zonnenberg BA, van Ufford-Mannesse PQ, de Vries MM, Links TP, Lips CJ & Voest EE. A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 2007 92 3466-3469.
24. Dora JM, Leie MA, Netto B, Fogliatto LM, Silla L, Torres F & Maia AL. Lack of imatinib-induced thyroid dysfunction in a cohort of non-thyroidectomized patients. European Journal of Endocrinology 2008 15 8771-8772.
25. Wu SY, Green WL, Huang WS, Hays MT & Chopra IJ. Alternate pathways of thyroid hormone metabolism. Thyroid 2005 15 943-958.
26. Pacini F, Sherman S, Schlumberger M, Elisei R,Wirth L, Bastholt L, Droz JP, Martins R, Hofmann M, Locati L, Eschenberg M & Stepan D. Exacerbation of postsurgical hypothyroidism during treatment of advanced differentiated (DTC) or medullary (MTC) thyroid carcinoma with AMG 706. Hormone Research 2007 68 29.
27. Sherman S, Wirth L, Droz JP, Hofmann M, Bastholt L, Martins R, Licitra L, Eschenberg M, SunYN, Juan T, Stepan D, Schlumberger M & for the Motesanib Thyroid Cancer Study Group Motesanib diphosphate in progressive differentiated thyroid cancer. New England Journal of Medicine 2008 359 31-42.
28. Rosen LS, Kurzrock R, Mulay M, Van Vugt A, Purdom M, Ng C, Silverman J, Koutsoukos A, Sun YN, Bass MB, Xu RY, Polverino A, Wiezorek JS, Chang DD, Benjamin R & Herbst RS. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. Journal of Clinical Oncology 2007 25 2369-2376.
29. Polverino A, Coxon A, Starnes C, Diaz Z, DeMelfi T, Wang L, Bready J, Estrada J, Cattley R, Kaufman S, Chen D, Gan Y, Kumar G, Meyer J, Neervannan S, Alva G, Talvenheimo J, Montestruque S, Tasker A, Patel V, Radinsky R & Kendall R. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Research 2006 66 8715-8721.
30. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G & Trail PA. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Research 2004 64 7099-7109.
31. http://www.fda.gov/medwatch/safety/2007/Mar_PI/Nexavar_PI.pdf.
32. Chi KN, Ellard SL, Hotte SJ, Czaykowski P, Moore M, Ruether JD, Schell AJ, Taylor S, Hansen C, Gauthier I, Walsh W & Seymour L. phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. Annals of Oncology 2008 19 746-751.
33. Eisen T, Ahmad T, Flaherty KT, Gore M, Kaye S, Marais R, Gibbens I, Hackett S, James M, Schuchter LM, Nathanson KL, Xia C, Simantov R, Schwartz B, Poulin-Costello M, O'Dwyer PJ & Ratain MJ. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. British Journal of Cancer 2006 95 581-586.
34. Gupta V, Puttaswamy K & Lassoued W. Sorafenib targets BRAF and VEGFR in metastatic thyroid carcinoma. Journal of Clinical Oncology 2007 25 6019.
35. Tamaskar I, Bukowski R, Elson P, Ioachimescu AG, Wood L, Dreicer R, Mekhail T, Garcia J & Rini BI. Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Annals of Oncology 2008 19 265-268.
36. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, LynchM& Carter C. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Research 2006 66 11851-11858.
37. Kim S, Yazici YD, Calzada G, Wang ZY, Younes MN, Jasser SA, El-Naggar AK & Myers JN. Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Molecular Cancer Therapeutics 2007 6 1785-1792.
38. Rivas M & Santisteban P. TSH-activated signaling pathways in thyroid tumorigenesis. Molecular and Cellular Endocrinology 2003 213 31-45.
39. Calebiro D, de Filippis T, Lucchi S, Martinez F, Porazzi P, Trivellato R, Locati M, Beck-Peccoz P & Persani L. Selective modulation of protein kinase A I and II reveals distinct roles in thyroid cell gene expression and growth. Molecular Endocrinology 2006 20 3196-3211.
40. Garfield D, Hercbergs A & Davis P. Unanswered questions regarding the management of sunitinib-induced hypothyroidism. Nature Clinical Practice. Oncology 2007 12 674-675.
41. Garfield DH, Wolter P, Schoffski P, Hercbergs A & Davis P. Documentation of thyroid function in clinical studies with sunitinib: why does it matter? Journal of Clinical Oncology 2008 26 5131-5132.
42. Wolter P, Stefan C, Decallonne B, Dumez H, Fieuws S, Wildiers H, Clement P, Debaere D, Van Oosterom A & Schoffski P. Evaluation of thyroid dysfunction as a candidate surrogate marker for efficacy of sunitinib in patients (pts) with advanced renal cell cancer (RCC). Journal of Clinical Oncology 2008 26 5126.